• Isabelle K Delattre, Flora T Musuamba, Roger K Verbeeck, Thierry Dugernier, Herbert Spapen, Pierre-François Laterre, Xavier Wittebole, Jean Cumps, Fabio S Taccone, Jean-Louis Vincent, Frédérique Jacobs, and Pierre E Wallemacq.
• Unit of Clinical Biochemistry, Université Catholique de Louvain, Avenue Hippocrate, 10, B-1200 Brussels, Belgium.
• Clin. Biochem. 2010 Apr 1;43(6):589-98.

ObjectivesThe study aims to develop empirical models able to predict the pharmacokinetics (PK) of four beta-lactams using the amikacin (AMK) therapeutic drug monitoring (TDM), in order to optimize their dosage regimens.Design And Methods69 critically ill septic patients were included. All received a first dose of AMK combined with piperacillin/tazobactam, ceftazidime, cefepime or meropenem. A multivariate analysis was performed to predict the beta-lactam PK using AMK PK parameters estimated from TDM and using pathophysiological variables.ResultsAn optimal prediction model was identified for each PK parameter of each beta-lactam. The best predictor of each model was one of the AMK PK parameters estimated from TDM. Other variables included colloid solution, renal and hepatic biomarkers, age and body weight.ConclusionPK of the four beta-lactams could be easily and rapidly predicted in critically ill septic patients using the AMK TDM. These predictions could improve the beta-lactam dosages in clinical practice.Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

31 keywords...

hide…